Editas Medicine Inc. (NASDAQ:EDIT) traded down 3.2% on Friday . The stock traded as low as $24.64 and last traded at $24.79, with a volume of 104,534 shares. The stock had previously closed at $25.62.

Several equities research analysts have weighed in on the company. Cowen and Company restated a “buy” rating on shares of Editas Medicine in a research note on Monday, May 16th. Zacks Investment Research upgraded Editas Medicine from a “sell” rating to a “hold” rating in a research note on Tuesday, July 5th. Jefferies Group restated a “hold” rating and set a $35.00 target price on shares of Editas Medicine in a research note on Friday, June 10th. Finally, Vetr upgraded Editas Medicine from a “hold” rating to a “buy” rating and set a $32.50 target price for the company in a research note on Monday, May 9th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $33.50.

The company’s 50-day moving average price is $30.45 and its 200 day moving average price is $30.73. The stock’s market capitalization is $891.37 million.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings results on Monday, May 16th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by $0.50. The company had revenue of $0.80 million for the quarter, compared to the consensus estimate of $1.08 million. On average, equities analysts predict that Editas Medicine Inc. will post ($2.35) earnings per share for the current fiscal year.

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.